Evidence map›Paper›PMID 26456830›Full record

ArticleCell reports2015

TIMELESS Forms a Complex with PARP1 Distinct from Its Complex with TIPIN and Plays a Role in the DNA Damage Response.

Lauren M Young, Antonio Marzio, Pablo Perez-Duran, Dylan A Reid, Daniel N Meredith, Domenico Roberti, Ayelet Star, Eli Rothenberg, Beatrix Ueberheide, Michele Pagano

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. PARP1 Suppression Drives ROS Resistance in Aneuploid Cancer Cells.bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  14. Article
  15. The TIMELESS effort for timely DNA replication and protection.Cellular and molecular life sciences : CMLS · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Lauren M YoungDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Perlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Antonio MarzioDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Perlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Pablo Perez-DuranDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Perlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, New York University School of Medicine, New York, NY 10016, USA.
Dylan A ReidPerlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
Daniel N MeredithGoogle, Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94114 USA.
Domenico RobertiDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Perlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Ayelet StarSackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Eli RothenbergPerlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
Beatrix UeberheidePerlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Proteomics Resource Center, Office of Collaborative Science, New York University School of Medicine, New York, NY 10016, USA.
Michele PaganoDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Perlmutter NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Howard Hughes Medical Institute, New York University School of Medicine, New York, NY 10016, USA. Electronic address: michele.pagano@nyumc.org.
New York University · USGoogle (United States) · USTel Aviv University · IL

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3M
REGULATION OF THE GI PHASE BY THE UBIQUITIN PATHWAYR01GM057587 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAGANO, MICHELE · 1998 to 2018
$7.8M
PH REGULATION OF CONNEXIN43--INTERMEDIARY STEPSR01GM057691 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI DELMAR, MARIO · 1999 to 2016
$5.6M
F-box proteins: deregulated cell cycle control and proteolysis in cancerR37CA076584 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAGANO, MICHELE · 2006 to 2016
$4.7M
F-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in CancerR01CA076584 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAGANO, MICHELE · 1998 to 2021
$4.5M
Training program in Molecular BiophysicsT32GM088118 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI STOKES, DAVID L. · 2010 to 2019
$1.8M
Single-Molecule Studies of Non-Homologous DNA End JoiningR01GM108119 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTHENBERG, ELI · 2015 to 2019
$1.7M
Single-molecule studies of BRCA1-BACH1 mechanism in genomic integrityR21CA187612 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTHENBERG, ELI · 2015 to 2016
$451k
Single-Molecule Studies of Human RECQ5 Helicase MechanismsR21GM110385 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTHENBERG, ELI · 2014 to 2014
$168k
Fbxo18-mediated proteasomal degradation in the process of aging.F30AG038215 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI YOUNG, LAUREN MEREDITH · 2011 to 2013
$141k
Howard Hughes Medical InstituteNCI NIH HHS 5T32CA009161NCI NIH HHS CA187612NCI NIH HHS P30 CA016087NCI NIH HHS P30CA016087NCI NIH HHS R01 CA076584NCI NIH HHS R21 CA187612NCI NIH HHS R37 CA076584NCI NIH HHS R37-CA076584NCI NIH HHS T32 CA009161NIA NIH HHS F30 AG038215NIA NIH HHS F30AG038215NIGMS NIH HHS GM057691NIGMS NIH HHS GM108119NIGMS NIH HHS GM110385NIGMS NIH HHS R01 GM057587NIGMS NIH HHS R01 GM057691NIGMS NIH HHS R01 GM108119NIGMS NIH HHS R21 GM110385NIGMS NIH HHS T32 GM088118NIGMS NIH HHS T32GM088118
6 · The paper itself

Abstract

PARP1 is the main sensor of single- and double-strand breaks in DNA and, in building chains of poly(ADP-ribose), promotes the recruitment of many downstream signaling and effector proteins involved in the DNA damage response (DDR). We show a robust physical interaction between PARP1 and the replication fork protein TIMELESS, distinct from the known TIMELESS-TIPIN complex, which activates the intra-S phase checkpoint. TIMELESS recruitment to laser-induced sites of DNA damage is dependent on its binding to PARP1, but not PARP1 activity. We also find that the PARP1-TIMELESS complex contains a number of established PARP1 substrates, and TIMELESS mutants unable to bind PARP1 are impaired in their ability to bind PARP1 substrates. Further, PARP1 binding to certain substrates and their recruitment to DNA damage lesions is impaired by TIMELESS knockdown, and TIMELESS silencing significantly impairs DNA double-strand break repair. We hypothesize that TIMELESS cooperates in the PARP1-mediated DDR.

Indexed as

DNA DamageDNA RepairAmino Acid SequenceBinding SitesCarrier ProteinsCell Cycle ProteinsCell Line, TumorDNA-Binding ProteinsHEK293 CellsHumansIntracellular Signaling Peptides and ProteinsMolecular Sequence DataNuclear ProteinsPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesProtein BindingCarrier ProteinsCell Cycle ProteinsDNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsNuclear ProteinsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesTIMELESS protein, humanTipin protein, human

Identifiers

PMID26456830
PMCPMC4618055
OpenAlexW2155633900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.